Effect of Pegvisomant on GH/IGF-I Relationship in GHD
Status:
Terminated
Trial end date:
2005-07-01
Target enrollment:
Participant gender:
Summary
Approximately 50% of middle-aged patients with severe AGHD have a normal age-related serum
IGF-I. It remains unclear if in these individuals serum IGF-I is GH dependent or independent.
This study compared the relationship between GH and serum IGF-I in two cohorts of male
patients with severe AGHD; one with normal and the other with subnormal age-related serum
IGF-I values. The GH receptor antagonist - pegvisomant was be used to specifically inhibit GH
action and the changes in markers of the GH axis, such as serum IGF-I, IGFBP-3, GH and GHBP
were measured.